UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________

 

FORM 8-K/A

_____________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

Date of report (Date of earliest event reported): May 4, 2015

 

 

TG Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

Delaware (State or Other Jurisdiction of Incorporation)

001-32639 (Commission File Number)

36-3898269 (IRS Employer Identification No.)

 

 

 

3 Columbus Circle, 15^th Floor

New York, New York 10019

(Address of Principal Executive Offices)

 

 

(212) 554-4484

(Registrant's telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

£

Written communications pursuant to Rule 425 under the Securities Act.

£

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

£

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

£

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

 

Explanatory Note

 

This Form 8-K/A is filed by TG Therapeutics, Inc. (“TG” or the “Company”) to correct Item 2.02 of the Current Report on Form 8-K dated May 4, 2015, which originally reported the Company would host an investor conference call at 8:30am EST. This conference call with occur at 8:00am EDT on May 5, 2015.

 

 

Item 2.02.

Results of Operations and Financial Condition.

 

On May 4, 2015, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the first quarter ended March 31, 2015. TG also announced that on Tuesday, May 5, 2015 at 8:00am EDT, TG would host an investor conference call during which the Company would provide a brief financial overview of its first quarter financial results and provide a business outlook for the remainder of 2015. A copy of such press release is being furnished as Exhibit 99.1.

  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	TG Therapeutics, Inc.
	(Registrant)
Date: May 4, 2015
	By:	/s/ Sean A. Power
		Sean A. Power
		Chief Financial Officer